Akorn, Mylan and Teva have been tipped to receive “soon” US Food and Drug Administration approvals for the first generics of Allergan’s controversial Restasis (cyclosporine) 0.05% ophthalmic solution, with market entry possible by the end of 2020, Bernstein forecasts.
In 2019, a series of unfavorable legal rulings for the originator – which is now a part of AbbVie –...




